Schwartzentruber et al. reported a phase III clinical trial evaluating the additional therapeutic effects of gp100 peptide vaccine on HD IL-2 therapy for advanced melanoma with Human Leukocyte Antigen (HLA)*A0201, suggesting that the vaccine-IL-2 group achieved significant improvements in ORR and progress-free survival (PFS) compared to the HD IL-2-alone group [16]. The gene discussed is IL2; the disease is melanoma.